Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Frankel

Showing results (71-80 of 147) with videos related to

Pageof 15
Sort By:
Oncotarget|October 6, 2017
Correction: Genomic mutation-driven metastatic breast cancer therapy: a single center experienceYuan Yuan, Susan E Yost, John Yim, et al.
Oncotarget|January 7, 2017
Genomic mutation-driven metastatic breast cancer therapy: a single center experienceYuan Yuan, Susan E Yost, John Yim, et al.
Journal of Cell Science|April 26, 2014
A crucial role for DOK1 in PDGF-BB-stimulated glioma cell invasion through p130Cas and Rap1 signallingAngela Barrett, Ian M Evans, Antonina Frolov, et al.
Leukemia & Lymphoma|February 20, 2016
A phase I pharmacodynamic study of GTI-2040, an antisense oligonucleotide against ribonuclotide reductase, in acute leukemias: a California Cancer Consortium studyMark H Kirschbaum, Paul Frankel, Timothy W Synold, et al.
Neuro-Oncology Advances|January 6, 2022
Repeatability of tumor perfusion kinetics from dynamic contrast-enhanced MRI in glioblastomaRyan T Woodall, Prativa Sahoo, Yujie Cui, et al.
Journal of Biomedical Optics|June 30, 2019
Improved antibody-guided surgery with a near-infrared dye on a pegylated linker for CEA-positive tumorsPaul Yazaki, Thinzar Lwin, Megan Minnix, et al.
Journal of Cancer Research and Clinical Oncology|May 18, 2007
Oblimersen and alpha-interferon in metastatic renal cancer: a phase II study of the California Cancer ConsortiumKim Margolin, Timothy W Synold, Primo Lara, et al.
Haematologica|January 18, 2015
A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphomaRobert Chen, Paul Frankel, Leslie Popplewell, et al.
Breast (Edinburgh, Scotland)|December 4, 2014
Pathologic complete response rates in triple-negative, HER2-positive, and hormone receptor-positive breast cancers after anthracycline-free neoadjuvant chemotherapy with carboplatin and paclitaxel with or without trastuzumabArvind M Shinde, Jing Zhai, Kim Wai Yu, et al.
Oncotarget|November 8, 2017
A phase I clinical trial of binimetinib in combination with FOLFOX in patients with advanced metastatic colorectal cancer who failed prior standard therapyMay Cho, Jun Gong, Paul Frankel, et al.
Pageof 15

Showing results (71-80 of 147) with videos related to

Sort By:
Pageof 15
Oncotarget|October 6, 2017
Correction: Genomic mutation-driven metastatic breast cancer therapy: a single center experienceYuan Yuan, Susan E Yost, John Yim, et al.
Oncotarget|January 7, 2017
Genomic mutation-driven metastatic breast cancer therapy: a single center experienceYuan Yuan, Susan E Yost, John Yim, et al.
Journal of Cell Science|April 26, 2014
A crucial role for DOK1 in PDGF-BB-stimulated glioma cell invasion through p130Cas and Rap1 signallingAngela Barrett, Ian M Evans, Antonina Frolov, et al.
Leukemia & Lymphoma|February 20, 2016
A phase I pharmacodynamic study of GTI-2040, an antisense oligonucleotide against ribonuclotide reductase, in acute leukemias: a California Cancer Consortium studyMark H Kirschbaum, Paul Frankel, Timothy W Synold, et al.
Neuro-Oncology Advances|January 6, 2022
Repeatability of tumor perfusion kinetics from dynamic contrast-enhanced MRI in glioblastomaRyan T Woodall, Prativa Sahoo, Yujie Cui, et al.
Journal of Biomedical Optics|June 30, 2019
Improved antibody-guided surgery with a near-infrared dye on a pegylated linker for CEA-positive tumorsPaul Yazaki, Thinzar Lwin, Megan Minnix, et al.
Journal of Cancer Research and Clinical Oncology|May 18, 2007
Oblimersen and alpha-interferon in metastatic renal cancer: a phase II study of the California Cancer ConsortiumKim Margolin, Timothy W Synold, Primo Lara, et al.
Haematologica|January 18, 2015
A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphomaRobert Chen, Paul Frankel, Leslie Popplewell, et al.
Breast (Edinburgh, Scotland)|December 4, 2014
Pathologic complete response rates in triple-negative, HER2-positive, and hormone receptor-positive breast cancers after anthracycline-free neoadjuvant chemotherapy with carboplatin and paclitaxel with or without trastuzumabArvind M Shinde, Jing Zhai, Kim Wai Yu, et al.
Oncotarget|November 8, 2017
A phase I clinical trial of binimetinib in combination with FOLFOX in patients with advanced metastatic colorectal cancer who failed prior standard therapyMay Cho, Jun Gong, Paul Frankel, et al.
Pageof 15